<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686413</url>
  </required_header>
  <id_info>
    <org_study_id>D3690C00018</org_study_id>
    <secondary_id>EudraCT No. 2007-004852-35</secondary_id>
    <nct_id>NCT00686413</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects</brief_title>
  <acronym>PET</acronym>
  <official_title>An Open Label Positron Emission Tomography (PET) Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects (Non Nicotine Users)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being performed in order to learn more about AZD3480 (potential as treatment for
      patients with Alzheimer's Disease) and to investigate how much of AZD3480 is bound to the
      nicotinic receptors in the brain at different concentrations of AZD3480 in blood, as well as
      to investigate the period of time for this binding.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration (AUC, Cmax, tmax)</measure>
    <time_frame>During time period of the PET assessement</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The whole brain uptake and regional distribution of radioligand 2-[18F]-F-A85380 following single intravenous (iv) microdose will be assessed (using derived radioactivity measurements).</measure>
    <time_frame>One on baseline day and one at the drug treatment day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SafetyAEs and vital signs.</measure>
    <time_frame>During the whole study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3480</intervention_name>
    <description>single dose, oral</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>2-[18F]-F-A85380</intervention_name>
    <description>Single dose, IV</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physically Healthy volunteers

          -  Genotyped with regard to CYP2D6

          -  Normal MRI scan at Visit 2

        Exclusion Criteria:

          -  Known or suspected drug or alcohol abuse or positive drugs of abuse screen as judged
             by the investigator.

          -  Participation in a PET examination as part of a scientific study during the past
             twelve months.

          -  Prescribed or non-prescribed from two weeks prior to the first PET examination.
             Occasional paracetamol and nasal spray for congestion will be allowed as medication.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Göran , Hårdemark, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Neuroscience TA AstraZeneca R&amp;D Södertälje, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Fransson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca Clinical Pharmacology Unit, C2-84, Karolinska University Hospital Huddinge, Stockholm, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <last_update_submitted>December 8, 2010</last_update_submitted>
  <last_update_submitted_qc>December 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hans-Göran Hårdemark, MD, PhD, Medical Science Director Clinical Neuroscience TA</name_title>
    <organization>AstraZeneca R&amp;D Södertälje</organization>
  </responsible_party>
  <keyword>PET</keyword>
  <keyword>AZD3480</keyword>
  <keyword>PET examination</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

